A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model
Craig H. Moskowitz(Memorial Sloan Kettering Cancer Center), Joachim Yahalom, David J. Straus(Cornell University), Ariela Noy, Richard C. Frank(Memorial Sloan Kettering Cancer Center), Stephen D. Nimer(University of Miami), Eric Hedrick(Biogen (United States)), Tania Trippett(Memorial Sloan Kettering Cancer Center), Nancy Coady-Lyons(Memorial Sloan Kettering Cancer Center), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Janine Walits(Memorial Sloan Kettering Cancer Center), Jing Qin(Memorial Sloan Kettering Cancer Center), André Goy(Rutgers, The State University of New Jersey), Joseph R. Bertino(Rutgers, The State University of New Jersey), James P. O'Brien(Memorial Sloan Kettering Cancer Center), Diane C. Louie(Memorial Sloan Kettering Cancer Center), Daniel A. Filippa(Memorial Sloan Kettering Cancer Center), Carol S. Portlock(Memorial Sloan Kettering Cancer Center), Maria Gonzales(Memorial Sloan Kettering Cancer Center)
Cited by 427
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k